HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The plasma pharmacokinetics of fosfomycin and metronidazole after intraperitoneal administration in patients undergoing appendectomy for uncomplicated appendicitis.

Abstract
We aimed to investigate the pharmacokinetics of fosfomycin and metronidazole after intraperitoneal administration of the combination of fosfomycin and metronidazole in patients undergoing laparoscopic appendectomy for uncomplicated appendicitis. We included eight otherwise healthy men undergoing laparoscopic appendectomy. The trial treatment was administered at the end of the surgical procedure and left in the abdominal cavity. Trial drugs consisted of 4 g fosfomycin and 1 g metronidazole in a total volume of 500.2 mL. Blood samples were collected prior to and ½, 1, 2, 4, 8, 12 and 24 h after administration. High-performance liquid chromatography-mass spectrometry was used for the measurement of plasma concentrations, and pharmacokinetic calculations were undertaken. Antimicrobial susceptibility testing was undertaken on isolates from intraoperatively collected specimens. The median maximal concentration for fosfomycin in plasma was 104.4 mg/L, median time point for the maximal concentration was 1.5 h, median half-life 3.0 h, and median area under the curve 608 mg*h/L. The median maximal concentration for metronidazole in plasma was 13.6 mg/L, median time point for the maximal concentration was 2.0 h, median half-life 7.3 h, and median area under the curve was 164 mg*h/L. All aerobic bacteria were susceptible to fosfomycin, and all anaerobes were susceptible to metronidazole. Plasma concentrations of fosfomycin and metronidazole were in line with concentrations reported from pharmacokinetic studies after intravenous administration and were within therapeutic ranges.
AuthorsSiv Fonnes, Johan Juhl Weisser, Barbara Juliane Holzknecht, Magnus Arpi, Jacob Rosenberg
JournalFundamental & clinical pharmacology (Fundam Clin Pharmacol) Vol. 34 Issue 4 Pg. 504-512 (Aug 2020) ISSN: 1472-8206 [Electronic] England
PMID31944378 (Publication Type: Clinical Trial, Phase II, Journal Article)
Copyright© 2020 Société Française de Pharmacologie et de Thérapeutique.
Chemical References
  • Anti-Bacterial Agents
  • Drug Combinations
  • Metronidazole
  • Fosfomycin
Topics
  • Adolescent
  • Adult
  • Anti-Bacterial Agents (administration & dosage, blood, pharmacokinetics)
  • Appendectomy (adverse effects)
  • Appendicitis (surgery)
  • Denmark
  • Drug Combinations
  • Drug Monitoring
  • Fosfomycin (administration & dosage, blood, pharmacokinetics)
  • Humans
  • Laparoscopy (adverse effects)
  • Male
  • Metronidazole (administration & dosage, blood, pharmacokinetics)
  • Middle Aged
  • Models, Biological
  • Postoperative Care
  • Prospective Studies
  • Surgical Wound Infection (microbiology, prevention & control)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: